ACUTE AND LATE TOXICITY OF PELVIC RADIOTHERAPY AND CONCOMITANT HYPOFRACTIONATED IMRT BOOST COMBINED WITH HORMONAL THERAPY FOR HIGH-RISK PROSTATE CANCER

被引：0
|
作者：
Quon, H. [1 ]
Loblaw, A. [1 ]
Morton, G. [1 ]
Sixel, K. [1 ]
Pang, G. [1 ]
Basran, P. [2 ]
Szumacher, E. [1 ]
Danjoux, C. [1 ]
Choo, R. [3 ]
Thomas, G. [1 ]
Kiss, A. [1 ]
Deabreu, A. [1 ]
Cheung, P. [1 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Odette Canc Ctr, Toronto, ON, Canada
[3] Mayo Clin, Rochester, NY USA
来源：
RADIOTHERAPY AND ONCOLOGY | 2010年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
143
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [21] ACUTE AND LATE TOXICITY OF HYPOFRACTIONATED RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: IMRT VS. HELICAL TOMOTHERAPY
    Rese, Annaisabel
    Pastore, Francesco
    Toledo, Diego
    Francomacaro, Ferdinando
    Ametrano, Gianluca
    Cammarota, Fabrizio
    Iorio, Vincenzo
    ANTICANCER RESEARCH, 2019, 39 (03) : 1599 - 1600
  • [22] Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
    Mekhail Anwar
    Vivian Weinberg
    Zachary Seymour
    I. Joe Hsu
    Mack Roach
    Alex R. Gottschalk
    Radiation Oncology, 11
  • [23] Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
    Anwar, Mekhail
    Weinberg, Vivian V.
    Seymour, Zachary
    Hsu, I. Joe
    Roach, Mack, III
    Gottschalk, Alex R.
    RADIATION ONCOLOGY, 2016, 11
  • [24] Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy
    Arunsingh, Moses
    Mallick, Indranil
    Prasath, Sriram
    Arun, B.
    Sarkar, Sandip
    Shrimali, Raj Kumar
    Chatterjee, Sanjoy
    Achari, Rimpa
    MEDICAL DOSIMETRY, 2017, 42 (01) : 18 - 23
  • [25] IMRT pelvic radiotherapy with simultaneous integrated boost in high-risk prostate cancer: Results after 10 years.
    Ekanger, Christian
    Dahl, Olav
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate-and high-risk prostate cancer
    Reddy, Krishna
    Strom, Tobin
    Plimpton, Reed
    Kavanagh, Brian D.
    Petersen, Jane
    Wilson, Shandra
    Maroni, Paul
    Raben, David
    JOURNAL OF RADIATION ONCOLOGY, 2014, 3 (04) : 401 - 407
  • [27] Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer.
    Wang, Michael
    Pearcey, Robert
    Pervez, Nadeem
    Yee, Don
    Mihai, Alina
    Patel, Samir
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [28] Effectiveness and toxicity of the intensity modulated radiotherapy (IMRT) as hypofractionated boost with prostate carcinoma
    Kosakowski, J.
    Welzel, G.
    Abo-Madyan, Y.
    Mai, S.
    Wertz, H.
    Wenz, F.
    Lohr, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 : 21 - 21
  • [29] PHASE I TRIAL OF PELVIC NODAL DOSE ESCALATION WITH HYPOFRACTIONATED IMRT FOR HIGH-RISK PROSTATE CANCER
    Adkison, Jarrod B.
    McHaffie, Derek R.
    Bentzen, Soren M.
    Patel, Rakesh R.
    Khuntia, Deepak
    Peteret, Daniel G.
    Hong, Theodore S.
    Tome, Wolfgang
    Ritter, Mark A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 184 - 190
  • [30] Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (01) : 21 - 27
12345